cancer immunotherapy
Personalized Cancer Vaccines Show Promise for Melanoma
Personalized Cancer Vaccines Show Promise for Melanoma
Jef Akst | Jul 6, 2017
In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse. 
Gene Mutations Foretell Immunotherapy Response
Gene Mutations Foretell Immunotherapy Response
Aggie Mika | Jun 12, 2017
A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes. 
Hitting It Out of the Park
Hitting It Out of the Park
Mary Beth Aberlin | Apr 1, 2017
Cancer can be as evasive and slippery as a spitball, but new immunotherapies are starting to connect.
Making CAR T-Cell Therapy Safer
Making CAR T-Cell Therapy Safer
Catherine Offord | Apr 1, 2017
Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.
Tasmanian Devil Cancer Immunotherapy
Tasmanian Devil Cancer Immunotherapy
Bob Grant | Mar 13, 2017
Researchers in Australia claim to have successfully used immunotherapy to treat devil facial tumor disease.
Kite’s CAR T-Cell Therapy Success
Kite’s CAR T-Cell Therapy Success
Jef Akst | Mar 1, 2017
More than one-third of lymphoma patients in a Phase 2 trial were clear of disease at six months, and no new safety concerns arose since the company’s three-month follow up.
FDA Approves Bladder Cancer Immunotherapy
FDA Approves Bladder Cancer Immunotherapy
Jef Akst | May 23, 2016
The US Food and Drug Administration greenlights Roche’s Tecentriq, which blocks a protein that obstructs the immune system’s ability to fight cancer.
AACR Q&A: Elaine Mardis
AACR Q&A: Elaine Mardis
The Scientist Staff | Apr 18, 2016
The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.
Napster Cofounder Launches Cancer Initiative
Napster Cofounder Launches Cancer Initiative
Bob Grant | Apr 13, 2016
Billionaire Silicon Valley entrepreneur Sean Parker donates $250 million to unite the cancer research community around the common goal of developing new immunotherapies.
Speaking of Science
Speaking of Science
The Scientist Staff | Apr 1, 2016
April 2016's selection of notable quotes